Pharmaceuticals
News Releases
News releases related to tuberculosis
2021
2020
2018
2017
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)
Pharmaceuticals
Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
2016
2015
Pharmaceuticals
Winner Announced for the 2015 Young Innovator in TB Research Award
Pharmaceuticals
Efficacy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
The Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
2014
Pharmaceuticals
A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26
Pharmaceuticals
After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
Pharmaceuticals
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)
2013
Pharmaceuticals
CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Pharmaceuticals